Sign in
CompletedPhase 4

Suvorexant and Sleep/Delirium in ICU Patients

Key facts

Who runs it
Beth Israel Deaconess Medical Center
Where
Boston and The Bronx, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
100 people enrolled
Started
28 Feb 2020
Ended
1 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Suvorexant 20 mg
  • Placebo oral tablet
Record updated
27 October 2025

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 60 years or older
  • Undergoing elective coronary artery bypass graft surgery with or without aortic and/or mitral valve replacement, who are expected to be transferred to the ICU postoperatively

Who cannot take part

  • Psychiatric or neurologic diseases (including chronic benzodiazepine use, bipolar disorder, psychotic disorder, posttraumatic stress disorder, requirement of prophylactic psychiatric medication, evidence of acute depression on screening visit, preexisting cognitive impairment, Alzheimer disease, Parkinson's disease, medications for cognitive decline, history of recent seizures (within 1 year prior visit), alcoholism or documented history of alcohol abuse, and narcolepsy)
  • Liver failure (CHILD-Pugh>4)
  • Patients with known hypersensitivity to study medications
  • Preoperative left ventricular ejection fraction of less than 30%
  • Renal failure (creatinine >2 mg/dl or dialysis dependence)
  • Coma (RASS<-1)
  • Signs and symptoms of delirium and agitation at time of enrollment (CAM-ICU positive)
  • Montreal Cognitive Assessment (MoCA) below 23 at time of consent
  • Severe sleep apnea requiring home continuous positive airway pressure treatment
  • Morbid obesity (BMI >40)
  • Known or suspected pregnancy (there are no adequate and well-controlled studies of suvorexant in pregnant women. Based on animal data, Suvorexant may cause fetal harm)
  • English language limitations (Sleep assessment and delirium assessment tools are only validated in English)
  • Patients enrolled in other interventional studies which could confound the primary endpoint

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United States
  • Montefiore Medical Center-Albert Einstein College of MedicineThe Bronx, United States

About the trial

What the trial wants to find out

Investigators will evaluate the efficacy of postoperative oral suvorexant treatment on nighttime wakefulness after persistent sleep onset (WASO) among adult cardiac surgical patients recovering in the cardiac intensive care unit (ICU). The study include patients ≥ 60 years old undergoing coronary artery bypass graft surgery (CABG), with or without valve surgery (aortic or mitral). Patients will receive either oral suvorexant or placebo for 7 nights starting the night after extubation. The primary hypothesis is that suvorexant compared with placebo decreases WASO, as measured by a specialized electroencephalogram (EEG), the SedLine monitor, during the first night in the cardiac ICU. Investigators will also assess total sleep time (TST), time to sleep onset (TSO), and postoperative delirium and delirium-free days.

The 2 groups in the trial

  • SuvorexantExisting treatment, for comparison

    Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.

    Treatment: Suvorexant 20 mg

  • PlaceboPlacebo, for comparison

    Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.

    Treatment: Placebo oral tablet

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of the Orexin Receptor Antagonist Suvorexant on Sleep Architecture and Delirium in the Intensive Care Unit: A Multi-Centric Randomized Controlled Trial
Publications
Record updated
27 October 2025